Neurocrine Biosciences has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the companies’ wider central-nervous-system-focused collaboration remains on track.
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and ...
LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a ...
Saniona AB ( (SE:SANION)) just unveiled an announcement. Saniona AB has announced new leadership appointments to enhance its clinical development, translational medicine, toxicology, and CMC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results